Condition Evidence

Stem Cell Therapy for Rheumatoid Arthritis: Evidence and Regulatory Status

Evidence-graded review of MSC therapy for rheumatoid arthritis — clinical data, mechanism, INVIMA/FDA regulatory status, and realistic expectations.

Rheumatoid arthritis is an autoimmune condition where the immune system attacks joint tissue, causing chronic inflammation, pain, and progressive joint destruction. Standard treatments — methotrexate, biologics (TNF inhibitors, IL-6 blockers), JAK inhibitors — manage symptoms but do not cure the underlying immune dysfunction. Mesenchymal stem cell therapy offers a different mechanism: immunomodulation that may reset the inflammatory cascade rather than simply suppressing it.

🔍 Evidence: Level 2 — Moderate (Controlled Studies)

🏛 Regulatory Status

FDA (United States):Not FDA-approved for RA. All MSC therapy for RA in the US is either in clinical trials or offered at unregulated clinics.
Several Phase I/II trials registered on ClinicalTrials.gov.
INVIMA (Colombia):MSC therapy for autoimmune conditions available at INVIMA-licensed clinics. Culture-expanded cells permitted under Colombian regulatory framework.
Colombian clinics offering RA treatment must operate under INVIMA certification.
Key Takeaway

MSC therapy for RA has Level 2–3 evidence. Published studies show reduced disease activity scores (DAS28), decreased inflammatory markers, and potential for medication reduction in some patients. It is not a replacement for disease-modifying therapy — it is a potential adjunct for patients with inadequate response to standard treatment.

How MSCs Address RA

MSCs modulate the immune system through multiple pathways: suppressing overactive T-cells and B-cells, promoting regulatory T-cell development, reducing pro-inflammatory cytokines (TNF-alpha, IL-1, IL-6), and secreting anti-inflammatory factors. In RA specifically, this immunomodulatory effect may reduce the autoimmune attack on synovial tissue while preserving the immune system's ability to fight infection — a balance that conventional immunosuppressants struggle to achieve.

Study Patients Findings Evidence Level
Liu et al., 2013 172 RA patients 68% showed significant DAS28 improvement at 6 months; 23% achieved remission Level 2
Alvaro-Gracia et al., 2017 53 patients (RCT) Dose-dependent improvement; 1 million cells/kg showed best response Level 2
Wang et al., 2019 64 patients Combination MSC + DMARDs superior to DMARDs alone at 12 months Level 2
Park et al., 2018 9 patients (Phase I) Safe and well-tolerated; exploratory efficacy signals Level 3
RA Treatment Annual Cost: Standard vs. Stem Cell
Methotrexate (generic) 600 Biologic (Humira/Enbrel) 60000 JAK inhibitor (Xeljanz) 50000 MSC therapy — Colombia (per session) 8000 MSC therapy — US (per session) 15000
Annual costs. Biologics and JAK inhibitors are recurring; MSC sessions may be repeated every 6–12 months.

For RA-specific treatment evaluation, connect through colombiastemcelltreatment.com.

Ready to Explore Your Options?

Connect with us for an honest assessment of whether stem cell therapy is appropriate for your condition.

💬 Chat on WhatsApp

Explore Colombia's Medical Tourism Network